DFTX Definium Therapeutics, Inc.
Definium Therapeutics, Inc. (DFTX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $1.2M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer | Sell 10b5-1 | 31,550 | $36.57 | $1.2M | 2,213,090 −1.4% of holding | |
| Sullivan Mark | Chief Legal Officer | Sell 10b5-1 | 14,051 | $36.57 | $513.8K | 494,228 −2.8% of holding | |
| Karlin Daniel | Chief Medical Officer | Sell 10b5-1 | 10,853 | $36.57 | $396.9K | 792,846 −1.4% of holding | |
| Roberts Brandi | Chief Financial Officer | Sell 10b5-1 | 3,377 | $36.57 | $123.5K | 394,528 −0.8% of holding | |
| Wiley Matthew T. | Chief Commercial Officer | Sell 10b5-1 | 3,097 | $36.57 | $113.3K | 359,036 −0.9% of holding | |
| Barrow Robert | Chief Executive Officer | Sell 10b5-1 | 19,023 | $37.94 | $721.7K | 1,494,640 −1.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.